HBIO

HARVARD BIOSCIENCE INC

Nasdaq· Laboratory Analytical Instruments· Inc. DE· CIK 0001123494 Biotech & Drug Discovery

$8.32 +0.09 (+1.09%)

Oct 26 4:00 PM ET · prev $8.23

Market cap

$38.0M

Nano cap

Consensus

Buy

75% Buy or better · 8 analysts

Median target

$7.50

−10% · range $7.50–7.50

Next earnings

Nov 10

in 14 days · EPS est. −$0.17

1 year

+108.0%

from $4.00 · Oct 27

30 days

+4.3%

from $7.98

52-week range

$4.00–8.56

−3% from high · low Oct 27

Avg volume 20D

17.1K

Oct 1 spike 45.7K

Short interest

🔒 Subscribers only

Insider net

+$202.4K

4 buyers · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 3 reports · 90 days

Balance 0 bearish · 0 bullish · 2 mixed · 1 neutral oldest → newest, height = score

Avg score

·High conf. 2/3 ·Next Earnings date, Nov 10, 2026

Strongest MIXED Harvard Bioscience reported Q2 2026 revenue of $22.7M, up 11% YoY, beating the $21.4M consensus estimate…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Mar 12 Harvard Bioscience reported full-year 2025 revenue of $86.6M, down f…
B Mar 16 to Mar 17 2 days of insider buys: $202.4K by 4 insiders, avg $4.94
R Mar 16 Two corporate insiders at Harvard Bioscience purchased shares in the…
R May 12 Harvard Bioscience reported Q1 2026 revenue of $20.8M, down 4.7% YoY…
R Aug 11 Harvard Bioscience reported Q2 2026 revenue of $22.7M, up 11% YoY, b…

Signal stack

Where each data set points today.

InsidersBULLISH

4 insiders bought $202.4K at an average $4.94. No open-market sales. Price is 69% above their cost.
InstitutionsBEARISH

Q2 2026: 1 added (0 new), 5 trimmed or exited.
AnalystsBULLISH

6 of 8 rate it Buy or better. Price is above every target.
EstimatesRISING

Current-quarter EPS estimate −$0.270 → −$0.170 over 90 days. 1 up, 0 down in 30 days.
TrendUPTREND

4% above its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
ROYAL BANK OF CANADA	NEAR_EXIT	15	—
MILLENNIUM MANAGEMENT LLC	TRIM	32,620	$200.6K
UBS Group AG	DOUBLED	17,581	$108.1K
JANE STREET GROUP, LLC	TRIM	13,982	$86.0K
GROUP ONE TRADING LLC	NEAR_EXIT	240	$1.5K
JPMORGAN CHASE & CO	NEAR_EXIT	195	$1.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts

Buy 75% rate it Buy or better

Strong Buy2Buy4Hold2Sell0Strong Sell0

12-month targets · 1 analysts

$8.32 $7.50 $7.50 $7.50

Price is above the highest target. Median implies −10%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 12, 2026	Benchmark MAINTAIN	MAINTAIN	Speculative Buy

Insider ledger

Form 4

$202.4K

bought · 4 insiders

sold · 0 insiders

+68.6%

vs their $4.94 cost

Date	Insider	Type	Value
Jun 9, 2026	Benson Seth Benjamin Director	AWARD	16,556 sh
Jun 9, 2026	Gagnon Robert E. Director	AWARD	16,556 sh
Jun 9, 2026	DENELSKY STEPHEN J Director	AWARD	16,556 sh
Jun 9, 2026	Eade Katherine A. Director	AWARD	16,556 sh
Jun 9, 2026	Snider William Director	AWARD	16,556 sh
Mar 20, 2026	Frost Mark T Chief Financial Officer	AWARD	30,000 sh
Mar 20, 2026	Duke John D Chief Executive Officer	AWARD	75,000 sh
Mar 17, 2026	DENELSKY STEPHEN J Director	BUY	$48.7K

Earnings setup

Estimates

Nov 10

reports in 14 days

−$0.17

EPS estimate, this quarter

+37%

estimate change, 90 days

1↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$0.270

90d

−$0.270

60d

−$0.270

30d

−$0.270

−$0.170

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.17	-$0.31–-$0.03	+37.0%	$21.8M
Next Q	$0.23	$0.16–$0.30	+119.0%	$24.5M
Current FY	-$0.38	-$0.62–-$0.14	+45.7%	$89.8M
Next FY	$0.65	$0.37–$0.92	+46.6%	$94.5M